AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Genenta Science shares surge 10.71% premarket as TEM-GBM study shows 44% 18-month survival rate and expansion into renal cell carcinoma trials.
ByAinvest
Monday, Nov 24, 2025 4:59 am ET1min read
Genenta Science surged 10.71% in premarket trading following an update on its TEM-GBM study for glioblastoma, highlighting improved 18-month survival rates (44% vs. 38%) and a patient achieving three-year survival without additional treatment. The company also announced expansion into a Phase 1/2a trial for metastatic renal cell carcinoma, reinforcing its oncology pipeline. Additionally, Genenta reported $30 million in cash reserves post-funding, bolstering confidence in its ability to advance clinical programs. These developments underscored progress in Temferon’s potential to alter survival outcomes in aggressive cancers, driving investor optimism.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet